Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NANO-X IMAGING LTD filings document foreign private issuer disclosures for a medical imaging technology company with ordinary shares listed under NNOX. Recent Form 6-K reports cover financial results, GAAP and non-GAAP measures, business updates, FDA 510(k) clearance for TAP2D on Nanox.ARC and Nanox.ARC X systems, and commercial developments involving Nanox.ARC deployment.
The filing record also includes capital-structure and governance disclosures, including a registered direct offering of ordinary shares, material agreements, incorporation of exhibits into Form F-3 and Form S-8 registration statements, and annual general meeting proxy materials. These documents describe shareholder voting matters, financing activity, operating results, regulatory updates and corporate reporting controls for the company.
Nano-X Imaging Ltd is issuing 3,826,530 ordinary shares in a registered direct offering to a single institutional investor at $3.92 per share, raising gross proceeds of about $15.0 million. After placement agent fees and expenses, the company expects net proceeds of approximately $14.2 million, which it plans to use for general working capital and corporate purposes.
The offering implies an immediate dilution of about $2.35 per share to the new investor, based on an as adjusted net tangible book value of $1.57 per share as of September 30, 2025. As context, there were 65,382,892 ordinary shares outstanding as of September 30, 2025, so this deal modestly increases the share count. Nanox also highlights recent milestones, including expanded FDA clearances, a CE mark in Europe for its Nanox.ARC system, and a proposed acquisition of VHC IT for up to $800,000 to support U.S. deployment of its AI imaging solutions.
Nanox Imaging Ltd entered into a securities purchase agreement with a single institutional investor for a registered direct offering of 3,826,530 ordinary shares at $3.92 per share. The agreement includes customary representations, warranties, and indemnification provisions for both the company and the purchaser. Closing of the offering is expected on November 25, 2025, subject to customary closing conditions. The company also furnished a related press release as an exhibit and reminded readers that any forward-looking statements are subject to significant business, regulatory, geopolitical, and macroeconomic risks.
NANO-X IMAGING LTD filed a Form 6-K reporting that it issued a press release on November 20, 2025, furnishing its latest financial results. The company explains that the press release includes both U.S. GAAP financial information and additional non-GAAP financial measures that exclude certain expenses required under GAAP, and directs readers to the press release for details on those adjustments.
The GAAP financial statement tables in the press release are incorporated by reference into Nano-X Imaging’s existing registration statements on Form F-3 (File No. 333-271688) and Form S-8 (File No. 333-248322), linking the updated financial information to previously filed offerings and equity compensation plans.
NANO-X IMAGING LTD reported that it will hold its Annual General Meeting of Shareholders on December 22, 2025 at 3:00 p.m. Israel time (8:00 a.m. EST) at its offices in Ofer Tech Park, Petach Tikva, Israel. Shareholders are being provided with a Notice and Proxy Statement and a Proxy Card, which are attached as exhibits to this report. The company also states that the information in this report is incorporated by reference into its existing registration statements on Form F-3 (File No. 333-271688) and Form S-8 (File No. 333-248322).
Daniel Ran, listed as the Chief Financial Officer of Nano-X Imaging Ltd. (NNOX), reported a direct purchase of ordinary shares on 09/05/2025. The Form 4 shows he acquired 1,000 ordinary shares at a price of $3.65 per share and, following the transaction, beneficially owned 6,950 ordinary shares in total. The filing indicates this is an individual filing by one reporting person and includes no derivative transactions.
Daniel Ran filed an Initial Statement of Beneficial Ownership (Form 3) for Nano-X Imaging Ltd. (NNOX) dated 09/05/2025. The filing shows Mr. Ran is an officer (CFO) and a director and beneficially owns 5,950 ordinary shares directly. He also holds two option grants exercisable for ordinary shares: 40,000 options exercisable from 09/30/2022 and expiring 09/30/2031 with an exercise price of $23.86, and 55,000 options exercisable from 05/23/2024 and expiring 05/23/2033 with an exercise price of $11.52. The filing lists a Forest Hills, NY address for the reporting person and is signed by Daniel Ran on 09/05/2025.
NANO-X IMAGING LTD furnished an update for August 2025 noting that it issued a press release on August 12, 2025, which is attached as an exhibit. The release includes financial results that use non-GAAP measures, meaning certain items are adjusted out of the standard U.S. GAAP figures.
The non-GAAP metrics specifically exclude legal and related expenses tied to legal matters described in note 3 to the company’s condensed consolidated financial statements. The GAAP financial statement tables in the press release are also incorporated by reference into the company’s existing Form F-3 and Form S-8 registration statements.